

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

DAFLON 500 mg, film-coated tablet

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

For a film-coated tablet:

Micronized purified flavonoid fraction ..... 500 mg

Corresponding to:

. Diosmin (90 %) ..... 450 mg

. Flavonoids expressed as hesperidin (10 %) ..... 50 mg

For a full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Film-coated tablet.

### 4. CLINICAL PARTICULARS

#### 4.1. Therapeutic indications

- Treatment of symptoms related to venolymphatic insufficiency (heavy legs, pain, early morning restless legs).
- Treatment of functional symptoms related to acute hemorrhoidal attack.

#### 4.2. Posology and method of administration

- Usual dosage: 2 tablets daily in two divided doses, midday and evening at meal times.
- Acute hemorrhoidal attack: 6 tablets per day for the first 4 days, then 4 tablets per day for 3 days.

#### 4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

#### 4.4. Special warnings and special precautions for use

The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

#### 4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. However and taking into consideration the huge post marketing experience on the product, no drug interaction has been reported to date.

#### 4.6. Fertility, pregnancy and lactation

Pregnancy:

No teratogenic effects have been shown in several studies and no adverse effect have been reported in human.

Breast-feeding:

In the absence of data on excretion in milk, treatment should be avoided during breast-feeding.

Fertility:

Reproductive toxicity studies showed no effect on fertility in male and female rats (see section 5.3).

#### 4.7. Effects on ability to drive and use machines

No studies on the effects of flavonoid fraction on the ability to drive and use machines have been performed. However, on the basis of the overall safety profile of flavonoid fraction, DAFLON® 500 mg has no or negligible influence on these abilities.

#### 4.8. Undesirable effects

Summary of the safety profile

Side effects reported with Daflon in clinical trials are of mild intensity. They consist mainly in gastro intestinal events (diarrhoea, dyspepsia, nausea, vomiting).

Tabulated list of adverse reactions

The following adverse effects or events have been reported and are ranked using the following frequency: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ); not known (cannot be estimated from the available data).

System Organ Class	Frequency	Preferred Term
Nervous system disorders	Rare	Dizziness
		Headache
		Malaise
Gastrointestinal disorders	Common	Diarrhoea
		Dyspepsia
		Nausea, Vomiting
	Uncommon	Colitis
	Not known*	Abdominal pain
Skin and subcutaneous tissue disorders	Rare	Pruritus
		Rash
		Urticaria
	Not known*	Isolated face, lip, eyelid oedema. Exceptionally Quincke's oedema

\* Post-marketing experience

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via ADR Reporting Website: [www.medicinesauthority.gov.mt/adrportal](http://www.medicinesauthority.gov.mt/adrportal).

## **4.9. Overdose**

No case of overdose with DAFLON® 500 mg has been reported.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1. Pharmacodynamic properties**

Pharmacotherapeutic group: Venotonic and vascular protector.

ATC code: C05CA53.

#### ➤ **Pharmacology**

It is active upon the return vascular system in the following way:

- it reduces venous distensibility and stasis,
- in the microcirculation, it normalises capillary permeability and increases capillary resistance.

#### ➤ **Clinical pharmacology**

Double blind controlled studies using methods by which the effects of the product on venous haemodynamics could be demonstrated and quantified have confirmed the above pharmacological properties in man.

- Dose-effect relationship: a statistically significant dose-effect relationship was established with respect to venous plethysmographic parameters: capacitance, distensibility and rate of emptying. The optimum dose-effect ratio was obtained with 2 tablets.
- Venous tonic activity: DAFLON® 500 mg increases venous tone: venous occlusion plethysmography with a mercury stress gauge demonstrated a decrease in the rate of emptying.
- Microcirculatory activity: double-blind controlled studies showed a statistically significant difference between placebo and the drug. In patients presenting with signs of capillary fragility, DAFLON® 500 mg increases capillary resistance, as measured by angiostrerometry.

#### ➤ **Clinical trials**

Double-blind placebo-controlled trials have demonstrated the activity of the drug in phlebology, in the treatment of chronic venous insufficiency of the lower limbs (both functional and organic).

### **5.2. Pharmacokinetic properties**

In man, following oral administration of the substance containing <sup>14</sup>C Diosmin:

- Excretion is mainly faecal, a mean of 14% of the dose administered is excreted in the urine.
- The elimination half-life is 11 hours.
- The drug is extensively metabolised as evidenced by the presence of various phenol acids in the urine.

### **5.3. Preclinical safety data**

In animals, experimental studies did not show any teratogenic effect.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1. List of excipients**

Tablet core: gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc.

Film-coating: glycerol, macrogol 6000, magnesium stearate, methylhydroxypropylcellulose, red iron oxide (E172), sodium lauryl sulfate, titanium dioxide, yellow iron oxide (E172).

### **6.2. Incompatibilities**

Not applicable.

### **6.3. Shelf life**

4 years.

### **6.4. Special precautions for storage**

Store below 30°C.

### **6.5. Nature and contents of container**

30 tablets in heat-sealed blister packs (PVC/aluminium).

### **6.6. Instructions for use and handling**

No special requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Les Laboratoires Servier  
50, rue Carnot  
92284 Suresnes cedex  
France

## **8. MARKETING AUTHORISATION NUMBER**

MA 066/00501

## **9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION**

26<sup>th</sup> October 2005 / 4<sup>th</sup> February 2013

**10. DATE OF REVISION OF THE TEXT**

4th February 2016